27 September 2017
Reporter: Barney Dixon

Amgen sues Mylan over Neulasta

Amgen has sued Mylan at the US District Court for the Western District of Pennsylvania over patents relating to its Neulasta (pegfilgrastim) chemotherapy support drug.

In February, the US Food and Drug Administration (FDA) accepted Mylan’s abbreviated Biologics License Application (aBLA) for the Neulasta biosimilar for review, but the FDA is yet to approve the application.

In its complaint, Amgen explained that approval of the biosimilar and Mylan’s potential importation and sale of its product would be “infringing”.

Both Amgen and Mylan started exchanging information in March this year under the so-called ‘patent dance’ procedure of the Biologics Price Competition and Innovation Act (BPCIA).

However, Amgen suggested that Mylan failed to provide certain information and “materially prejudiced and impeded Amgen’s ability to review the Mylan aBLA”.

Amgen alleged that Mylan “failed to provide other information that describes the process or processes used to manufacture the biological product that is the subject of’ the Mylan aBLA”.

In June, Amgen took to the US Supreme Court to challenge a US Court of Appeals for the Federal Circuit decision that said the patent dance procedures were completely optional and that a biosimilar applicant can decide to withhold a copy of its biosimilar application.

Amgen said the patent dance was part of the BPCIA’s trade-off and balanced the rights of reference products against those of biosimilar applicants.

The case was sent back to the court of appeals to for a further ruling.

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Patent perception must shift, says Schecter
13 December 2017 | London | Reporter: Barney Dixon
Public perception must shift if the US is to find feasible solutions to patent abuse, according to chief patent counsel at IBM Manny Schecter
Patent owners winning in IPR
12 December 2017 | New York | Reporter: Barney Dixon
Patent owners are winning more than losing in IPR proceedings, according to a study from law firm Fitzpatrick, Cella, Harper & Scinto
High tech companies weigh in on Allergan deal
11 December 2017 | Washington DC | Reporter: Barney Dixon
Tech companies have argued that Allergan should not be allowed to circumvent the inter partes review process with its controversial patent deal with the Saint Regis Mohawk Tribe
BlackBerry to pay $137 million to Nokia
08 December 2017 | Waterloo | Reporter: Barney Dixon
BlackBerry will pay $137 million to Nokia after the International Chamber of Commerce’s International Court of Arbitration ruled against the company in a patent licensing dispute
ILO ruling “vote of no confidence” for Battistelli, says CSC
07 December 2017 | Munich | Reporter: Barney Dixon
In an open letter to the EPO’s heads of delegations, the CSC said that it interpreted the ILO’s decision as a “massive vote of no confidence in the president of the EPO"
China world’s top patent filer in 2016
07 December 2017 | Geneva | Reporter: Barney Dixon
China has emerged as the top patent filer in the world, accounting for nearly all of the 8 percent growth in patent applications in 2016
EPO president’s impartiality questioned at ILO
06 December 2017 | Geneva | Reporter: Barney Dixon
The International Labour Organisation has questioned the impartiality of EPO president Benoît Battistelli, in two tribunal decisions concerning an EPO employee, and found that there was a conflict of interest on the part of the president